Future Market Insights’ updated report estimates the global antibody discovery market size to grow by 2.6X over the next ten years- from USD 8.5 billion in 2024 to USD 21.8 billion by 2034. Global demand is anticipated to surge at 9.9% CAGR throughout the forecast period, indicating the growing importance of antibodies in modern medicine.
Phage display remains the most preferred method for antibody discovery globally, recording a CAGR of 9.7%. This can be attributed to its versatility, robustness, applicability, and other advantages.
| Attributes | Key Insights |
|---|---|
| Base Market Value (2023) | USD 7.6 billion |
| Market Size in 2024 | USD 8.5 billion |
| Market Revenue in 2034 | USD 21.8 billion |
| Value-based CAGR (2024 to 2034) | 9.9% |
Antibody therapeutics is transforming the field of medicine, offering a new ray of hope for patients with diseases that were considered untreatable previously. It has paved the way for the development of novel drug classes called therapeutic antibodies.
Growing popularity of therapeutic antibodies due to their specificity, potency, and versatility is set to boost market growth. These drugs are showing promising results in diseases like cancer and autoimmune diseases, which is fueling their demand.
Monoclonal antibodies, protein-based therapeutics, and other biologics offer several advantages over traditional small-molecule drugs. These include their greater specificity and minimal side effects. Growing interest in such biologics will create greater demand for antibody discovery technologies.
Widening application area of antibodies beyond therapeutics is another key factor boosting market growth. In the contemporary world, antibodies are being increasingly used in diagnostic applications like point-of-care testing and immunoassays. Similarly, their usage is increasing in research and biotechnology applications.
Ongoing advances in antibody technology are anticipated to result in the development of more effective treatments for several diseases. This will bode well for the market during the next ten years.
Companies are looking to develop next-generation antibody formats, including antibody-drug conjugates (ADCs), bispecific antibodies, and engineered antibodies with improved specificity and functionality. Similarly, novel technologies like AI and ML are being incorporated into discovery workflows. These factors will further boost growth of the target industry.
The global market recorded a robust CAGR of 12.4% during the historical period, with total market valuation reaching USD 7.6 billion in 2023. In the next ten years, a CAGR of 9.9% is on the cards for the target industry, depicting a deduction of 2.5% CAGR from the historical period. By 2034, the global antibody discovery market valuation is set to reach USD 21.8 billion.
| Historical CAGR (2019 to 2023) | 12.4% |
|---|---|
| Forecast CAGR (2024 to 2034) | 9.9% |
Historically, demand for global demand grew rapidly. This was mostly due to thriving biopharmaceutical industry and increased popularity of biologics, particularly during the COVID-19 pandemic.
Increased collaboration between some leading players and academic institutions also positively impacted the market. Similarly, a shift towards patient-centric drug development, coupled with increased demand for personalized medicine, boosted the market.
The future of antibody discovery market looks bright owing to rising cases of chronic diseases and escalating demand for novel therapies. Ongoing advances in antibody technologies will also play a key role in facilitating market growth.
Investigating new therapeutic areas such as pediatrics, neurology, and rare diseases is anticipated to uplift demand for antibody discovery through 2034. Increasing government support and favorable regulatory frameworks for developing and approving biologics like antibodies will also benefit the industry.
Advances in phage display, gene editing, and humanization techniques are facilitating the discovery process. They allow for the development of more specific and potent antibodies, which will directly impact market growth in coming years.
Growing Prevalence of Chronic and Infectious Diseases
One of the prominent factors influencing growth of the global market is the increasing incidence of chronic diseases like diabetes, cancer, and autoimmune diseases. These diseases often require novel treatments like antibodies.
Antibody-based therapies are becoming ideal tools for managing these chronic diseases due to their high effectiveness. They specifically bind to disease-causing molecules, thereby minimizing the risk of side effects. This, in turn, will create a high demand for antibody discovery services during the assessment period.
Rising Outsourcing Trends and High Investments in Research and Development
Leading biotechnology and pharmaceutical companies are rigorously investing in research and development to produce new antibody-based diagnostics and therapeutics. This is leading to the development of new technologies and platforms for antibody discovery.
Several pharmaceutical companies are also outsourcing their antibody discovery activities to prominent contract research organizations (CROs) to reduce costs and enhance their productivity. This will create lucrative growth opportunities for the target market.
There is no doubt that the antibody discovery industry has a bright future, especially in new therapeutics and diagnostics. However, it also faces certain challenges that might impact its growth.
One key challenge is the complex process of developing antibodies requiring substantial time and resources. Similarly, strict guidelines for antibody-based therapies and fierce competition are making it difficult for companies to survive in this industry.
The section comprehensively evaluates three interrelated markets: the global antibody discovery industry, the antibody purification service market, and the drug discovery service industry. It dissects each market's distinctive characteristics, encompassing their respective CAGRs, while delving into the pivotal factors influencing their growth trajectories.
Global Antibody Discovery Market Forecast:
| Attribute | Global Market Analysis |
|---|---|
| CAGR (2024 to 2034) | 9.9% |
| Growth Factor | Escalating demand for targeted therapies like antibody-based drugs is set to boost market growth. |
| Antibody Discovery Market Trends | Key growth-shaping trends include rising interest in personalized medicine and advances in biotechnology and immunology. |
Global Antibody Purification Service Market Forecast:
| Attribute | Global Antibody Purification Service Industry Outlook |
|---|---|
| CAGR (2024 to 2034) | 11.0% |
| Growth Factor | Escalating demand for high-quality antibodies is anticipated to boost growth of the antibody purification service market. |
| Key Trends | Growing adoption of antibody-based therapeutics will benefit the market. |
Global Drug Discovery Service Market Analysis:
| Attribute | Global Drug Discovery Service Demand Outlook |
|---|---|
| CAGR (2024 to 2034) | 14.5% |
| Growth Factor | Escalating need for novel drugs to tackle diseases like cancer and rare genetic disorders is set to propel demand for drug discovery services. |
| Key Trends | A key growth influencing trend is the integration of novel technologies like AI, ML, and data analytics in drug discovery. |
The table below shows the predicted growth rates of the key countries. South Korea, Japan, and the United Kingdom are set to record high CAGRs of 12.0%, 11.4%, and 11.1%, respectively, through 2034.
| Countries | CAGR (2024 to 2034) |
|---|---|
| United States | 10.2% |
| United Kingdom | 11.1% |
| China | 10.7% |
| Japan | 11.4% |
| South Korea | 12.0% |
The table below highlights key countries’ market revenues. The United States and China are forecast to remain leading markets, with predicted valuations of USD 3.9 billion and USD 3.4 billion, respectively, in 2034.
| Countries | Market Revenue (2034) |
|---|---|
| United States | USD 3.9 billion |
| United Kingdom | USD 880.5 million |
| China | USD 3.4 billion |
| Japan | USD 2.4 billion |
| South Korea | USD 1.4 billion |
The United States market is anticipated to grow at a robust CAGR of 10.2% during the forecast period, with total valuation reaching USD 3.9 billion by 2034. This can be attributed to rising cases of cancer and burgeoning demand for targeted therapies.
There has been a spike in cancer prevalence in the United States during the last few years, and the trend is set to escalate further in the coming years. According to the Centers for Disease Control and Prevention (CDC), the total number of cancer cases in the United States is estimated to increase by 49%, reaching 2,286,300 annual cases in 2050.
The high prevalence of cancer and other chronic diseases, in turn, is set to create a greater demand for therapeutic antibodies, thereby boosting market growth. Antibody-based therapies are becoming ideal solutions for attacking specific disease cells while leaving healthy cells unhealthy.
The United States is also home to several leading biopharmaceutical companies that are rigorously investing in antibody discovery research. This will have a positive impact on the United States market share and performance throughout the forecast period.
Future Market Insight’s latest analysis estimates China's industry value to total USD 3.4 billion by 2034. Demand in the country will probably surge at a CAGR of 10.7% throughout the forecast period.
Multiple factors are stimulating growth of China market. These include high burden of chronic diseases, increasing government initiatives and funding programs, and ongoing advances in antibody development technologies.
Amid changing lifestyles and growing geriatric population, there is a serious increase in chronic diseases like cancer and cardiovascular diseases in China. To counter this, antibody-based therapies are becoming promising treatment solutions, resulting in higher demand in the country.
The section below provides deeper insights into top segments and their respective values & shares in the global market. This information can help companies act accordingly and strengthen their presence in lucrative regions.
Based on method, the phage display segment is set to grow at 9.7% CAGR through 2034. By antibody type, the human antibody category will thrive at a CAGR of 9.5% from 2024 to 2034.
| Top Segment | Phage Display (Method) |
|---|---|
| CAGR (2024 to 2034) | 9.7% |
Phage display continues to remain the most preferred method owing to its versatility, robustness, and other advantages. The target segment accounted for a prominent market share of 47.0% in 2023 and is set to thrive at 9.7% CAGR through 2034.
Phage display has become a powerful tool for antibody discovery as it allows rapid screening of millions of antibodies. It is ideal for the creation of vast antibody libraries, allowing researchers to look for specific antibodies with optimal therapeutic characteristics.
Researchers are widely using the phage display method as it helps them to yield high-affinity antibodies ideal for diverse uses. These antibodies find applications in diagnostics, therapeutics, and research tools.
The ability of phage display technology to discover antibodies against complex targets is another key factor encouraging its adoption. Thus, it will continue to remain a key tool in modern antibody therapeutics during the assessment period.
| Top Segment | Human Antibody (Antibody Type) |
|---|---|
| CAGR (2024 to 2034) | 9.5% |
As per the latest analysis, the human antibody segment will retain its dominance in the global market through 2034, recording a CAGR of 9.5%. This can be attributed to high adoption of human antibodies in several applications due to their numerous advantages.
Human antibodies display enhanced safety profiles, enhanced efficacy, and reduced immunogenicity. As a result, their application area is widening, ranging from combating cancer and autoimmune disorders to their diagnostic applications.
Human antibodies’ compatibility with human targets improves therapeutic effectiveness while reducing the risk of adverse immune reactions. They align with the rising demand for personalized medicine.
Most regulatory bodies favor human antibodies due to their excellent safety profiles. Growing popularity of drugs developed using human antibodies will further boost growth of the target segment during the assessment period.
Several opportunities exist for companies amid burgeoning demand for antibodies for treating a wide range of diseases. To capitalize on this, top antibody discovery specialists are focusing on using advanced methods like hybridoma technology to create vast libraries of novel antibodies. Subsequently, they employ next-generation sequencing to analyze these libraries and identify promising candidates for specific biomarkers.
Automation is penetrating its roots in antibody production and purification processes, with companies looking to improve their throughput and efficiency. Top players are also adopting strategies like partnerships, collaborations, acquisitions, partnerships, and agreements to stay ahead of the curve.
Recent Developments:
Table 1: Global Market Value (US$ billion) Forecast by Region, 2019 to 2034
Table 2: Global Market Value (US$ billion) Forecast by Methods, 2019 to 2034
Table 3: Global Market Value (US$ billion) Forecast by Antibody Type, 2019 to 2034
Table 4: Global Market Value (US$ billion) Forecast by End User, 2019 to 2034
Table 5: North America Market Value (US$ billion) Forecast by Country, 2019 to 2034
Table 6: North America Market Value (US$ billion) Forecast by Methods, 2019 to 2034
Table 7: North America Market Value (US$ billion) Forecast by Antibody Type, 2019 to 2034
Table 8: North America Market Value (US$ billion) Forecast by End User, 2019 to 2034
Table 9: Latin America Market Value (US$ billion) Forecast by Country, 2019 to 2034
Table 10: Latin America Market Value (US$ billion) Forecast by Methods, 2019 to 2034
Table 11: Latin America Market Value (US$ billion) Forecast by Antibody Type, 2019 to 2034
Table 12: Latin America Market Value (US$ billion) Forecast by End User, 2019 to 2034
Table 13: Western Europe Market Value (US$ billion) Forecast by Country, 2019 to 2034
Table 14: Western Europe Market Value (US$ billion) Forecast by Methods, 2019 to 2034
Table 15: Western Europe Market Value (US$ billion) Forecast by Antibody Type, 2019 to 2034
Table 16: Western Europe Market Value (US$ billion) Forecast by End User, 2019 to 2034
Table 17: Eastern Europe Market Value (US$ billion) Forecast by Country, 2019 to 2034
Table 18: Eastern Europe Market Value (US$ billion) Forecast by Methods, 2019 to 2034
Table 19: Eastern Europe Market Value (US$ billion) Forecast by Antibody Type, 2019 to 2034
Table 20: Eastern Europe Market Value (US$ billion) Forecast by End User, 2019 to 2034
Table 21: South Asia and Pacific Market Value (US$ billion) Forecast by Country, 2019 to 2034
Table 22: South Asia and Pacific Market Value (US$ billion) Forecast by Methods, 2019 to 2034
Table 23: South Asia and Pacific Market Value (US$ billion) Forecast by Antibody Type, 2019 to 2034
Table 24: South Asia and Pacific Market Value (US$ billion) Forecast by End User, 2019 to 2034
Table 25: East Asia Market Value (US$ billion) Forecast by Country, 2019 to 2034
Table 26: East Asia Market Value (US$ billion) Forecast by Methods, 2019 to 2034
Table 27: East Asia Market Value (US$ billion) Forecast by Antibody Type, 2019 to 2034
Table 28: East Asia Market Value (US$ billion) Forecast by End User, 2019 to 2034
Table 29: Middle East and Africa Market Value (US$ billion) Forecast by Country, 2019 to 2034
Table 30: Middle East and Africa Market Value (US$ billion) Forecast by Methods, 2019 to 2034
Table 31: Middle East and Africa Market Value (US$ billion) Forecast by Antibody Type, 2019 to 2034
Table 32: Middle East and Africa Market Value (US$ billion) Forecast by End User, 2019 to 2034
Figure 1: Global Market Value (US$ billion) by Methods, 2024 to 2034
Figure 2: Global Market Value (US$ billion) by Antibody Type, 2024 to 2034
Figure 3: Global Market Value (US$ billion) by End User, 2024 to 2034
Figure 4: Global Market Value (US$ billion) by Region, 2024 to 2034
Figure 5: Global Market Value (US$ billion) Analysis by Region, 2019 to 2034
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 8: Global Market Value (US$ billion) Analysis by Methods, 2019 to 2034
Figure 9: Global Market Value Share (%) and BPS Analysis by Methods, 2024 to 2034
Figure 10: Global Market Y-o-Y Growth (%) Projections by Methods, 2024 to 2034
Figure 11: Global Market Value (US$ billion) Analysis by Antibody Type, 2019 to 2034
Figure 12: Global Market Value Share (%) and BPS Analysis by Antibody Type, 2024 to 2034
Figure 13: Global Market Y-o-Y Growth (%) Projections by Antibody Type, 2024 to 2034
Figure 14: Global Market Value (US$ billion) Analysis by End User, 2019 to 2034
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 17: Global Market Attractiveness by Methods, 2024 to 2034
Figure 18: Global Market Attractiveness by Antibody Type, 2024 to 2034
Figure 19: Global Market Attractiveness by End User, 2024 to 2034
Figure 20: Global Market Attractiveness by Region, 2024 to 2034
Figure 21: North America Market Value (US$ billion) by Methods, 2024 to 2034
Figure 22: North America Market Value (US$ billion) by Antibody Type, 2024 to 2034
Figure 23: North America Market Value (US$ billion) by End User, 2024 to 2034
Figure 24: North America Market Value (US$ billion) by Country, 2024 to 2034
Figure 25: North America Market Value (US$ billion) Analysis by Country, 2019 to 2034
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 28: North America Market Value (US$ billion) Analysis by Methods, 2019 to 2034
Figure 29: North America Market Value Share (%) and BPS Analysis by Methods, 2024 to 2034
Figure 30: North America Market Y-o-Y Growth (%) Projections by Methods, 2024 to 2034
Figure 31: North America Market Value (US$ billion) Analysis by Antibody Type, 2019 to 2034
Figure 32: North America Market Value Share (%) and BPS Analysis by Antibody Type, 2024 to 2034
Figure 33: North America Market Y-o-Y Growth (%) Projections by Antibody Type, 2024 to 2034
Figure 34: North America Market Value (US$ billion) Analysis by End User, 2019 to 2034
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 37: North America Market Attractiveness by Methods, 2024 to 2034
Figure 38: North America Market Attractiveness by Antibody Type, 2024 to 2034
Figure 39: North America Market Attractiveness by End User, 2024 to 2034
Figure 40: North America Market Attractiveness by Country, 2024 to 2034
Figure 41: Latin America Market Value (US$ billion) by Methods, 2024 to 2034
Figure 42: Latin America Market Value (US$ billion) by Antibody Type, 2024 to 2034
Figure 43: Latin America Market Value (US$ billion) by End User, 2024 to 2034
Figure 44: Latin America Market Value (US$ billion) by Country, 2024 to 2034
Figure 45: Latin America Market Value (US$ billion) Analysis by Country, 2019 to 2034
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 48: Latin America Market Value (US$ billion) Analysis by Methods, 2019 to 2034
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Methods, 2024 to 2034
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Methods, 2024 to 2034
Figure 51: Latin America Market Value (US$ billion) Analysis by Antibody Type, 2019 to 2034
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Antibody Type, 2024 to 2034
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Antibody Type, 2024 to 2034
Figure 54: Latin America Market Value (US$ billion) Analysis by End User, 2019 to 2034
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 57: Latin America Market Attractiveness by Methods, 2024 to 2034
Figure 58: Latin America Market Attractiveness by Antibody Type, 2024 to 2034
Figure 59: Latin America Market Attractiveness by End User, 2024 to 2034
Figure 60: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 61: Western Europe Market Value (US$ billion) by Methods, 2024 to 2034
Figure 62: Western Europe Market Value (US$ billion) by Antibody Type, 2024 to 2034
Figure 63: Western Europe Market Value (US$ billion) by End User, 2024 to 2034
Figure 64: Western Europe Market Value (US$ billion) by Country, 2024 to 2034
Figure 65: Western Europe Market Value (US$ billion) Analysis by Country, 2019 to 2034
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 68: Western Europe Market Value (US$ billion) Analysis by Methods, 2019 to 2034
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Methods, 2024 to 2034
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Methods, 2024 to 2034
Figure 71: Western Europe Market Value (US$ billion) Analysis by Antibody Type, 2019 to 2034
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Antibody Type, 2024 to 2034
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Antibody Type, 2024 to 2034
Figure 74: Western Europe Market Value (US$ billion) Analysis by End User, 2019 to 2034
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 77: Western Europe Market Attractiveness by Methods, 2024 to 2034
Figure 78: Western Europe Market Attractiveness by Antibody Type, 2024 to 2034
Figure 79: Western Europe Market Attractiveness by End User, 2024 to 2034
Figure 80: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 81: Eastern Europe Market Value (US$ billion) by Methods, 2024 to 2034
Figure 82: Eastern Europe Market Value (US$ billion) by Antibody Type, 2024 to 2034
Figure 83: Eastern Europe Market Value (US$ billion) by End User, 2024 to 2034
Figure 84: Eastern Europe Market Value (US$ billion) by Country, 2024 to 2034
Figure 85: Eastern Europe Market Value (US$ billion) Analysis by Country, 2019 to 2034
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 88: Eastern Europe Market Value (US$ billion) Analysis by Methods, 2019 to 2034
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Methods, 2024 to 2034
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Methods, 2024 to 2034
Figure 91: Eastern Europe Market Value (US$ billion) Analysis by Antibody Type, 2019 to 2034
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Antibody Type, 2024 to 2034
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Antibody Type, 2024 to 2034
Figure 94: Eastern Europe Market Value (US$ billion) Analysis by End User, 2019 to 2034
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 97: Eastern Europe Market Attractiveness by Methods, 2024 to 2034
Figure 98: Eastern Europe Market Attractiveness by Antibody Type, 2024 to 2034
Figure 99: Eastern Europe Market Attractiveness by End User, 2024 to 2034
Figure 100: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 101: South Asia and Pacific Market Value (US$ billion) by Methods, 2024 to 2034
Figure 102: South Asia and Pacific Market Value (US$ billion) by Antibody Type, 2024 to 2034
Figure 103: South Asia and Pacific Market Value (US$ billion) by End User, 2024 to 2034
Figure 104: South Asia and Pacific Market Value (US$ billion) by Country, 2024 to 2034
Figure 105: South Asia and Pacific Market Value (US$ billion) Analysis by Country, 2019 to 2034
Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 108: South Asia and Pacific Market Value (US$ billion) Analysis by Methods, 2019 to 2034
Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Methods, 2024 to 2034
Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Methods, 2024 to 2034
Figure 111: South Asia and Pacific Market Value (US$ billion) Analysis by Antibody Type, 2019 to 2034
Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Antibody Type, 2024 to 2034
Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Antibody Type, 2024 to 2034
Figure 114: South Asia and Pacific Market Value (US$ billion) Analysis by End User, 2019 to 2034
Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 117: South Asia and Pacific Market Attractiveness by Methods, 2024 to 2034
Figure 118: South Asia and Pacific Market Attractiveness by Antibody Type, 2024 to 2034
Figure 119: South Asia and Pacific Market Attractiveness by End User, 2024 to 2034
Figure 120: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 121: East Asia Market Value (US$ billion) by Methods, 2024 to 2034
Figure 122: East Asia Market Value (US$ billion) by Antibody Type, 2024 to 2034
Figure 123: East Asia Market Value (US$ billion) by End User, 2024 to 2034
Figure 124: East Asia Market Value (US$ billion) by Country, 2024 to 2034
Figure 125: East Asia Market Value (US$ billion) Analysis by Country, 2019 to 2034
Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 128: East Asia Market Value (US$ billion) Analysis by Methods, 2019 to 2034
Figure 129: East Asia Market Value Share (%) and BPS Analysis by Methods, 2024 to 2034
Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Methods, 2024 to 2034
Figure 131: East Asia Market Value (US$ billion) Analysis by Antibody Type, 2019 to 2034
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Antibody Type, 2024 to 2034
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Antibody Type, 2024 to 2034
Figure 134: East Asia Market Value (US$ billion) Analysis by End User, 2019 to 2034
Figure 135: East Asia Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 137: East Asia Market Attractiveness by Methods, 2024 to 2034
Figure 138: East Asia Market Attractiveness by Antibody Type, 2024 to 2034
Figure 139: East Asia Market Attractiveness by End User, 2024 to 2034
Figure 140: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 141: Middle East and Africa Market Value (US$ billion) by Methods, 2024 to 2034
Figure 142: Middle East and Africa Market Value (US$ billion) by Antibody Type, 2024 to 2034
Figure 143: Middle East and Africa Market Value (US$ billion) by End User, 2024 to 2034
Figure 144: Middle East and Africa Market Value (US$ billion) by Country, 2024 to 2034
Figure 145: Middle East and Africa Market Value (US$ billion) Analysis by Country, 2019 to 2034
Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 148: Middle East and Africa Market Value (US$ billion) Analysis by Methods, 2019 to 2034
Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Methods, 2024 to 2034
Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Methods, 2024 to 2034
Figure 151: Middle East and Africa Market Value (US$ billion) Analysis by Antibody Type, 2019 to 2034
Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Antibody Type, 2024 to 2034
Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Antibody Type, 2024 to 2034
Figure 154: Middle East and Africa Market Value (US$ billion) Analysis by End User, 2019 to 2034
Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 157: Middle East and Africa Market Attractiveness by Methods, 2024 to 2034
Figure 158: Middle East and Africa Market Attractiveness by Antibody Type, 2024 to 2034
Figure 159: Middle East and Africa Market Attractiveness by End User, 2024 to 2034
Figure 160: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
The global market is set to be valued at USD 8.5 billion in 2024.
Global demand is forecast to grow at a CAGR of 9.9% through 2034.
By 2034, the global market size is set to reach USD 21.8 billion.
The target industry registered a CAGR of 12.4% from 2019 to 2023.
The United States is predicted to record a CAGR of 10.2% through 2034.
FMI estimates the global antibody market value to total USD 581.42 billion by 2034.
The antibody therapy market size is set to reach USD 824.0 billion by 2033.
It is the process of identifying new antibodies that can bind to specific target molecules like proteins.
Explore Similar Insights
Antibody Discovery Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
